Skip to main content

Show 26 results Show all

Policy brief template: Scaling-Up Self-Injection of DMPA-SC to Increase Contraceptive Access and Options

This customizable document provides a brief description of DMPA-SC; an overview of evidence on how the product expands access through multiple delivery channels; and policy and advocacy recommendations for country decision-makers tied to the country’s stage of access.

Institutional author(s): PATH
Publication date: October, 2019

Important policies for advancing access to subcutaneous DMPA

Offers an overview of key policies that affect introduction and scale-up of injectable contraceptives, including DMPA-SC.

Institutional author(s): PATH
Publication date: 2019

Advocacy Strategy Development Template: Planning to Achieve DMPA-SC Policy Change

A 10-part framework that supports individuals and organizations to develop a high-impact, outcome-oriented policy advocacy strategy.

Institutional author(s): PATH
Publication date: August, 2019

Increasing access to subcutaneous DMPA in Uganda: An advocacy case study

Describes key evidence-building efforts, advocacy actions, and policy changes in Uganda brought about by key partners to increase access to injectable contraception, including DMPA-SC. You can draw on lessons learned from Uganda to inform your policy goals and advocacy strategy for increasing method choice and access with DMPA-SC in your country.

Institutional author(s): PATH
Publication date: August, 2019

DMPA and HIV: What advocates need to know

Summarizes important takeaways for advocates from the latest guidance released by the World Health Organization on hormonal contraception, including DMPA injectables, and HIV for women at high risk of HIV.

Institutional author(s): PATH
Publication date: August, 2019

Expanding Access to Injectable Contraceptives through Pharmacies Toolkit

This toolkit contains resources designed to help pharmacy associations become effective advocates and begin working to change policies in their countries. The toolkit can be adapted to advocate for any injectable contraceptive. The toolkit includes a Resource for Considering DMPA-SC.

Institutional author(s): SHOPS Plus, USAID
Publication date: May, 2019

Tool Web page

Key actions for advocates to advance subcutaneous DMPA

Provides examples of actions that may be useful in advancing access to DMPA-SC, including those that apply to different country stages.

Institutional author(s): PATH
Publication date: August, 2017

Common terms for DMPA injectable contraception

This DMPA-SC advocacy pack brief helps you understand the terms surrounding DMPA injectables to inform your messaging and communication.

Institutional author(s): PATH
Publication date: 2017

Insights and Recommendations for Facilitating DMPA-SC Self-Administration in India

This policy brief serves as a guide as DMPA-SC is being integrated into India’s family planning program. The policy recommendations, formulated through evidence and insights, pave the way for successful self-administration and maximization of benefits for clients.

Institutional author(s): Ipas Development Foundation
Publication date: 2023

Publication on Ipas website

DMPA-SC policy and regulatory advocacy landscape

This policy landscape can be leveraged by applicants interested in applying to the DMPA-SC Regulatory Advocacy Catalytic Opportunity Fund (COF). The landscape was originally developed in 2020 to understand policies and regulations, including over-the-counter regulations, that impact women’s access to DMPA-SC and identify short- and long-term advocacy opportunities. In 2022, it was refreshed to understand policy shifts and additional advocacy opportunities in a subset of 12 of the original 18 countries currently eligible for the Regulatory Advocacy COF. Insights from the policy landscape have informed the design and eligibility criteria of the Regulatory Advocacy COF, proactively identified opportunities, and provided frameworks and guidance for interested applicants.

Institutional author(s): Clinton Health Access Initiative (CHAI)
Publication date: 2022

Report